Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Austin Gold (AUST)
Intensity Therapeutics (INTS)
Genenta Science (GNTA)
Chicago Atlantic Real Estate Finance, Inc. (REFT)
Chicago Atlantic Real Estate Finance (REFI)
Nu Holdings Ltd. (NU)
Hashicorp, Inc. (HCP)
Fresh Vine Wine, Inc. (VINE)
Priced IPO
AeroClean Technologies (AERC)
Finwise Bancorp (FINW)
Kindercare Learning Companies, Inc. (KLC)
Snow Lake Resources (LITM)
Sweetgreen, Inc. (SG)
Usertesting, Inc. (USER)
Braze, Inc. (BRZE)
Sono Group N.v. (SEV)
Iris Energy Limited (IREN)
Mynaric Ag (MYNA)
Journey Medical Corporation? (DERM)
Tivic Health Systems (TIVC)
Blackboxstocks (BLBX)
Kidpik (PIK)
Vaxxinity, Inc. (VAXX)
Lulus Fashion Lounge Holdings, Inc. (LVLU)
Weave Communications, Inc. (WEAV)
Backblaze, Inc. (BLZE)
HeartBeam, Inc. (BEAT)
Rivian Automotive, Inc. (RIVN)
More companies

Ventyx Biosciences, Inc. (VTYX)

Sector - Healthcare

Price chart

+14.31%
Return from IPO

Company News

IPO Profile

About company

They are a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. They believe their ability to discover and develop differentiated product candidates in an efficient manner allows them to address well-established multi-billion-dollar commercial markets and positions them to become a leader in the immunology market. Their lead product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor. Its selectivity for TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms in preclinical studies supports the potential to avoid toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors. They believe VTX958 has the potential to address a broad range of immune-mediated diseases, such as psoriasis, inflammatory bowel disease (IBD), psoriatic arthritis and lupus, each of which represent multi-billion-dollar market opportunities. They plan to develop VTX958 initially for psoriasis, psoriatic arthritis and Crohn’s disease, among other potential indications.
Industry
Pharmaceutical Preparations
CEO CFO
-
Employees Founded
24 2018

Contacts

Address: 662 Encinitas Blvd, Suite 250 Encinitas, California 92024

Telephone: (760) 593-4832

Web page: http://www.ventyxbio.com

IPO information

First Trade Date 10/21/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 7.8
Shares Revised (MM) 9.5
Expected offer amount (MM) $124.8
Realized offer amount(MM) $152

Financial Data (last reporting year)

Market Cap (MM) $804.0
Revenues (MM) $0
Net Income (Loss) (MM) $-77.1

Voting

What do you think will happen with the VTYX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Jefferies

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Jefferies/ Evercore ISI/ Piper Sandler
CO-Managers
LifeSci Capital

Sector: Healthcare

Tweets about $VTYX

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats